r Folate deficiency during pregnancy is associated with restricted fetal growth, although the underlying mechanisms are poorly understood.
Introduction
Low maternal folate intake and reduced red blood cell folate levels are linked to restricted fetal growth (Tamura & Picciano, 2006; Fekete et al. 2012; van Uitert & Steegers-Theunissen, 2013) . Periconceptional folate deficiency is a risk factor for fetal structural malformations such as neural tube defects (NTDs) (Smithells et al. 1976; Czeizel & Dudas, 1992) . Conversely, maternal folic acid supplementation reduces the risk of NTDs (MRC, 1991) and, at least in some studies, increases birth weight (Iyengar & Babu, 1975; Iyengar & Rajalakshmi, 1975) . However, the mechanisms linking maternal folate levels to fetal growth and neural tube closure are poorly understood. Folate is a water-soluble B vitamin that is essential for the synthesis of purine and thymidine nucleotides, which are needed for DNA replication and repair (Stover, 2004) . Furthermore, adequate folate status is important for the production of S-adenosylmethionine (SAM), a universal donor of methyl groups for a number of methylation reactions, including DNA methylation, a process central to gene silencing (Stover, 2004) . Changes in DNA methylation and alterations in the synthesis of nucleotide precursors have been implicated in the development of NTDs (Blom et al. 2006; Wilde et al. 2014) .
Mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that is activated by amino acids, glucose, ATP, oxygen and growth factor signalling. mTOR functions as a master regulator of protein translation, thereby controlling cell growth, proliferation and metabolism (Dennis et al. 2001; Peng et al. 2002; Jacinto & Hall, 2003; Martin & Hall, 2005; Dann et al. 2007; Gulati & Thomas, 2007; Laplante & Sabatini, 2012; Wiczer & Thomas, 2012; Shimobayashi & Hall, 2014; Albert & Hall, 2015) . mTOR exists in two complexes, mTOR Complex 1 (mTORC1) and 2, with the protein raptor (regulatory associated protein of mTOR) associated to mTORC1 and rictor (rapamycin-insensitive companion of mTOR) associated to mTORC2. mTORC1 phosphorylates S6K1 (p70 S6 kinase) and 4E-BP1 (4-eukaryotic initiation factor binding protein-1), resulting in increased protein translation. mTORC2 phosphorylates Akt, protein kinase Cα (PKCα) and serum and glucocorticoid-regulated kinase (SGK) and influences the actin skeleton, regulates metabolism and promotes cell survival (Jacinto et al. 2004; Alessi et al. 2009; Laplante & Sabatini, 2012) . We have provided compelling evidence that both mTORC1 and mTORC2 are powerful positive regulators of placental amino acid transporters (Roos et al. 2007 (Roos et al. , 2009 Rosario et al. 2013 Rosario et al. , 2016a Chen et al. 2015) . Specifically, mTORC1 regulates trophoblast System A and System L amino acid transport at the post-translational level by influencing the trafficking of specific amino acid transporter isoforms to the plasma membrane by Nedd4-2 (neuronal precursor cell-expressed, developmentally downregulated gene 4 isoform 2)-mediated ubiquitination (Rosario et al. 2016a) . Placental mTORC1 activity is inhibited in human intrauterine growth restriction (IUGR) (Roos et al. 2007; Yung et al. 2008; Chen et al. 2015) and activated in placentas of large babies born to obese mothers . Furthermore, placental mTORC1 activity has been reported to be decreased in hyperthermia-induced IUGR in sheep (Arroyo et al. 2009) , in response to a maternal low protein diet in the rat (Rosario et al. 2011) and maternal calorie restriction in the baboon (Kavitha et al. 2014 ) and activated in a mouse model of maternal obesity associated with fetal overgrowth (Aye et al. 2015; Rosario et al. 2016b) . Importantly, placental amino acid transport has been reported to be changed in the same direction as mTOR signalling in these clinical conditions and animal models of altered fetal growth (Ross et al. 1996; Anderson et al. 1997; de Vrijer et al. 2004; Rosario et al. 2011; Kavitha et al. 2014; Aye et al. 2015; Chen et al. 2015) . Collectively, these data suggest that trophoblast mTOR signalling regulates fetal growth by modulating placental nutrient transport.
The primary mechanism by which mTOR controls cell growth is by regulating protein translation (Laplante & Sabatini, 2012) . mTOR is an amino acid sensor (Gulati & Thomas, 2007; Laplante & Sabatini, 2012; Efeyan et al. 2015) providing a direct link between amino acid availability, protein synthesis and cell growth. Cell growth and proliferation also require a sufficient supply of folate, partly due to its critical role in DNA repair and de novo DNA synthesis. Both folate deficiency (Tamura & Picciano, 2006; Fekete et al. 2012; van Uitert & Steegers-Theunissen, 2013 ) and inhibition of mTOR are associated with restricted fetal growth (Roos et al. 2007; Rosario et al. 2011; Kavitha et al. 2014; Chen et al. 2015) . These considerations provided the rationale to test the hypothesis that trophoblast mTOR functions as a folate sensor, representing a novel molecular link between folate availability and fetal growth. In the current study, we cultured primary human trophoblast (PHT) cells to explore the effect of folate deficiency on mTORC1 and mTORC2 signalling and used gene targeting approaches to determine the role of the proton-coupled folate transporter (PCFT) as a mechanistic link between folate availability and mTOR signalling.
Methods

Collection of placental tissue
Term placental tissue was collected from healthy pregnant women undergoing elective Caesarean section after written informed consent. Samples and medical information were added to a tissue repository approved by the Colorado Multiple Institutional Review Board (14-1073) and subsequently study personnel provided de-identified samples and clinical information used in this study.
Isolation and culture of PHT cells
Primary PHT cells were isolated and cultured in vitro (Kliman et al. 1986; Rosario et al. 2016a) . Cells were plated in either 60 mm culture dishes (ß5 × 10 6 cells per dish for Western blot analysis or six-well plates for methyl-tetrahydrofolate (MTHF) uptake experiments; ß3.75 × 10 6 cells per well for RNAi mediated gene silencing) and cultured in 5% CO 2 , 95% atmospheric air at 37°C for 90 h. PHT cells were cultured in normal cell culture media [Dulbecco's modified Eagle medium (DMEM)/Hams F-12, supplemented with L-glutamine, penicillin, streptomycin, gentamycin and 10% fetal bovine serum] or in low folate containing media, containing no folate except folate present in 10% serum (folate-free DMEM, Cat. No. D2429; Sigma, St. Louis, MO, USA) and Hams F12 (Cat. No. ME 110245L1; Invitrogen, Carlsbad, CA, USA) supplemented with L-glutamine, penicillin, streptomycin, gentamycin and 10% fetal bovine serum. Cell culture media were changed daily. We have previously reported that our PHT cells have a high expression of cytokeratin-7, a trophoblast-specific marker, with no detectable expression of vimentin, a marker for mesenchyme-derived cells Rosario et al. 2013) , confirming the high purity of our trophoblast cell population.
Folate deficiency in cultured PHT cells
To study the effect of folate deficiency on mTOR signalling, PHT cells were cultured in folate-deficient media for 24, 48, 72 or 90 h as illustrated in Fig. 1A .
Effect of homocysteine on mTOR signalling
PHT cells were cultured in DMEM + F12 medium with or without DL-homocystine (5, 20 or 100 μM l −1 ) for 10 h (between 80 and 90 h after plating). At 18, 42, 66, 90 h of culture, the media were removed and stored at −20°C for determination of human chorion gonadotropin (hCG).
Folate measurement in PHT cells
PHT cell lysates for determination of intracellular folate concentrations were prepared by incubating approximately 5 million PHT cells per 60 mm dish, which were cultured without antibiotics for 66-90 h. Subsequently, cells were scraped, collected, lysed in ascorbic acid (0.5%), sonicated and freeze thawed. Folate content in PHT cell lysates was measured by using a commercially available kit (ALPCO Diagnostic Products, Windham, NH, USA), according to the manufacturer's instructions.
Assessment of PHT cell differentiation and viability
To confirm that trophoblast cells were undergoing biochemical differentiation, and to assess cell viability, the release of hCG into the culture medium was measured using a commercial ELISA kit which detects the β-subunit of hCG (Immuno Biological Labs, Minneapolis, MN, USA). Syncytin expression was measured as an index of trophoblast cell-cell fusion and differentiation in culture. Antibodies directed against caspase-3 (R&D Systems, Minneapolis, MN, USA) were used to determine the presence of apoptosis in culture.
RNA interference-mediated silencing
Dharmafect 2 transfection reagent (Thermo Scientific, Rockford, IL, USA) and small interference RNAs (siRNAs) (Sigma-Aldrich), targeting PCFT (SASI Hs02 00362432), DEPTOR (DEP domain-containing mTOR-interacting protein; SASI 1297010-H/5582, 1297011-H) or a non-coding scrambled sequence (100 nM; sense: 5 GAUCAUACGUGCGAUCAGATT) were added to cultured PHT cells (ß3.75 × 10 6 cells per well in six-well plates; ß7.5 × 10 6 cells in 60 mm dish) after 18 h in culture and incubated for 24 h. Subsequently, siRNAs were removed and fresh medium was added. At 90 h in culture, silencing efficiency was determined at the protein and functional levels using Western blot.
System A and system L amino acid transport assay Amino acid uptake in cultured PHT cells was determined at 90 h in culture. The activity of System A and System L amino acid transporters was assessed by measuring the Na + -dependent uptake of [ 14 C]methylaminoisobutyric acid (MeAIB; 20 μM) and the J Physiol 595.13 2-amino-2-norbornane-carboxylic acid (BCH; 64 μM)-inhibitable uptake of [ 3 H] leucine (0.0125 μM), respectively, as described in detail previously .
MTHF uptake assay [3 ,5 ,7,9 -3H]-Methyltetrahydrofolic acid uptake in cultured PHT cells was determined at 90 h following plating. In brief, transport experiments were performed in a buffer with the following composition (in mM): 150 NaCl, 10 Hepes and 5.6 D-(+) glucose (pH 7.5 or 5.5). Initially, the culture medium was removed, and the cells were washed with buffer at 37°C; uptake was then initiated by the addition of 1 ml of buffer at 37°C containing 30 nM [ 3 H] MTHF (Moravek Biochemicals, Brea, CA, USA). Based on initial time course studies uptake was linear up to 120 min, and 80 min was therefore used at the time at which incubation was stopped by removing the incubation medium. Subsequently, the cells were placed on ice and rinsed with 1 ml of ice-cold PBS (pH 7.4). Non-mediated uptake was determined in the presence of 1.5 mM unlabelled MTHF. 
Western blotting
For immunoblotting, cells were lysed in PBS with 0.1% SDS containing phosphatase and protease inhibitors. Subsequently, cells were scraped, collected and sonicated. Western blotting was carried out as described . Protein expression of total and phosphorylated mTOR, S6K1 (Thr-389), 4E-BP1 (Thr-37/46 or Thr-70), S6 ribosomal protein (Ser-235/236) and Akt (Ser-473 or Thr-308) were analysed in cell lysates using commercial antibodies (Cell Signaling Technology, Boston, MA, USA). Target band densities were normalized to loading using beta-actin. For each protein target the mean density of the control sample bands was assigned an arbitrary value of 1. All individual densitometry values were expressed relative to this mean.
Proximity ligation assay and confocal microscopy
Isolated PHT cells (500,000 cells per well) were grown on chamber slides (Lab-Tek) for 90 h. The cells were fixed in ice-cold methanol at −20°C for 20 min and were blocked using 5% newborn calf serum (NCS) in PBS for 1 h followed by incubation in antibodies targeting PCFT (generated in rabbit) and mTOR (generated in mouse) for 2 h. Proximity ligation assay (PLA) probes anti-rabbit PLUS and anti-mouse MINUS were diluted in Duolink dilution buffer and incubated in a pre-heated humidity chamber for 1 h. This was followed by ligation, amplification and detection according to the Duolink In Situ Orange kit (Sigma-Aldrich) manufacturer's protocol. Confocal microscopy was performed using a Zeiss LSM 780 microscope at 63× magnification using oil immersion. Images were captured in the same laser settings with four Z-steps of 0.4 um.
Determination of placental mTOR signalling and maternal serum folate concentrations
Placentas were collected from term uncomplicated pregnancies as described above. In addition, maternal blood samples were collected prior to Caesarean section. Serum was prepared and frozen at −80°C until analysis of folate concentrations using an Immulite 1000 (Siemens Healthcare Diagnostics, Deerfield, IL, USA), according to the manufacturer's instructions. Intra-and inter-assay coefficients of variation were 6.7 and 7.9% at 700 pg ml −1 . Within 15 min of delivery, the decidua basalis and chorionic plate from placenta were removed and villous tissue was dissected and rinsed in cold physiological saline. The villous tissue was transferred to cold buffer D (250 mM sucrose, 10 mM Hepes, pH 7.4) containing 1:100 dilution of protease and phosphatase inhibitors (Sigma-Aldrich) and homogenized on ice with a Polytron (Kinematica, Luzern, Switzerland). The placental homogenates were frozen in liquid nitrogen and stored at −80°C until further processing. The phosphorylation of key proteins in the mTORC1 and 2 signalling pathways was determined using Western blots as described for cells.
Data presentation and statistics
Data are presented as means ± SEM or + SEM. The statistical significance of differences between control and experimental groups was assessed using an unpaired Student's t test, repeated measures ANOVA with Tukey-Kramer multiple comparisons post hoc test. A P value <0.05 was considered significant.
Results
Folate deficiency does not affect PHT cell viability, differentiation or apoptosis
Culturing PHT cells in low folate medium for up to 90 h did not influence the secretion of hCG, a well-established biochemical marker of syncytialization. After 66 h in culture, there was a marked increase in hCG production by trophoblast cells, and the levels remained high until at least 90 h after plating (data not shown). Because hCG is produced predominantly by syncytialized cells, these data provide evidence of cell differentiation. We demonstrate further that there was no difference in the protein expression of syncytin (a differentiation marker) or in the expression of apoptosis markers (total and phosphorylated p53 or caspase-3 and cleaved caspase-3; data not shown) in PHT cells cultured in folate-deficient media as compared to control cells. Collectively, these data indicate that culturing PHT cells in low folate media up to 90 h did not affect trophoblast cell viability and differentiation.
Intracellular folate levels
Intracellular folate concentrations of PHT cells cultured in folate-deficient medium were decreased by 88% (47 ± 3.4 ng/5 × 10 6 cells in control cells to 5.8 ± 3.2 ng/5 × 10 6 cells in folate-deficient cells, P < 0.0001; n = 5) as compared to control cells cultured in folate-sufficient medium.
Folate deficiency inhibits mTORC1 signalling
Time course studies indicated that 90 h of folate deficiency markedly affected mTORC1 (Fig. 1) . We studied the phosphorylation of S6K1, S6 ribosomal protein and 4E-BP1 as functional read-outs for mTORC1 activity in PHT cell lysates of control and folate-deficient cell (Fig. 1B, C) . Folate deficiency decreased the phosphorylation of S6K1 at Thr-389 by 75% in PHT J Physiol 595.13 cell lysates (P = 0.001; n = 6) as compared to control. Phosphorylation of ribosomal protein S6 (Ser-235/236), a component of the 40S ribosome and a physiologically relevant S6K1 substrate, was inhibited by 63% (P = 0.0004; n = 6) in folate-deficient PHT cells. Phosphorylation of 4E-BP1 occurs at multiple sites in an ordered manner. Phosphorylation by mTOR at Thr-37 and Thr-46 of 4E-BP1 may prime it for subsequent phosphorylation at sites including Ser-65 and Thr-70. The 4E-BP1 phosphorylation of Thr at 37/46 was significantly reduced in cell lysates of folate-deficient cells as compared to control (−59%, P < 0.004; n = 6). In contrast, phosphorylation of 4E-BP1 at Thr-70 was comparable between PHT cells of the control and folate-deficient groups. In addition, expression of raptor (−32%, P < 0.003; n = 6), a protein associated with mTORC1, decreased in response to folate deficiency. No significant differences were found in the expression of total S6K, S6 and 4E-BP1 between cell lysates of control and folate-deficient cells (Fig. 1B, C) .
Folate deficiency inhibits mTORC2 signalling
As shown in Fig. 2 , culturing PHT cells in low folate medium for 90 h significantly reduced the expression of rictor (−68%, P < 0.001; n = 6), a protein associated with mTORC2. In addition, folate deficiency inhibited mTORC2 activity (Fig. 2) as assessed by phosphorylation of Akt at Ser-473 (−72%, P < 0.004; n = 4) and SGK1 at Ser-422 (−83%, P < 0.0003; n = 4). Importantly, folate deficiency did not influence Akt phosphorylation at Thr-308 (Fig. 2) , a well-established target for the insulin/IGF-I signalling pathway, suggesting that the impact of low folate on cellular signalling is specific.
Returning folate-deficient PHT cells to folate-containing media normalizes mTOR signalling
To determine whether the mTOR inhibition in response to folate deficiency is reversible, PHT cells were grown in folate-deficient media for 90 h and subsequently cultured in media with normal folate concentrations for 10 h (Fig. 3A) . Culturing folate-deficient PHT 
Homocysteine does not affect mTOR signalling
Because folate is required for the metabolic conversion of homocysteine to methionine and folate deficiency results in accumulation of homocysteine, we determined whether incubation of PHT cells in homocysteine (5-100 μM) for 10 h (80-90 h of culture) inhibits mTORC1 and mTORC2 signalling. The concentrations of homocysteine (5-100 μM) used in the present study are comparable to pathophysiological levels observed in subjects with mild hyperhomocysteinemia (16-24 μM) (Girling & de Swiet, 1998) . When cultures were subsequently assessed for cell viability and differentiation, we found that incubation in homocysteine (up to 100 μM) for 10 h did not influence syncytialization or increase apoptosis (data not shown).
As and mTORC2 signalling activity (n = 4, Fig. 5 ) was unaffected following incubation in homocysteine. These data suggest that in cultured PHT cells, mTORC1 and mTORC2 are modulated by low folate rather than high homocysteine.
Folate deficiency inhibits system A and L amino acid transporter activity
To study the effect of folate deficiency on trophoblast amino acid uptake, we determined BCH-inhibitable [ 3 H] leucine uptake (System L) and Na + -dependent [ 14 C] MeAIB uptake (System A) at 90 h in culture. As shown in Fig. 6 , folate deficiency reduced System L uptake by 34% (n = 5; P < 0.04) and System A uptake by 33% (n = 5; P < 0.03) as compared to control.
Involvement of PCFT in folate sensing by mTORC1 and mTORC2
Substantial progress has been made in identifying the molecular mechanisms that form the basis for mTORC1 sensing of amino acids, which requires the recruitment of mTORC1 to the outer lysosomal surface, mediated by Rag GTPase-dependent and -independent mechanisms and involves the vacuolar H + -ATPase (Kim et al. 2008; Sancak et al. 2008 Sancak et al. , 2010 . Although the molecular identity of the sensor linking amino acid levels to mTORC1 signalling has remained elusive, recent reports demonstrate that the sodium-coupled neutral amino acid transporter 9 (SLC38A9) constitutes a key component of the lysosomal amino acid sensing machinery (Efeyan et al. 2015; Jewell et al. 2015; Wang et al. 2015) . We reasoned that a folate transporter interacts specifically with folate, thereby meeting one of the primary requirements of a folate sensor. PCFT is critical for folate uptake in the intestine (Qiu et al. 2006 (Qiu et al. , 2007 . Although PCFT is ubiquitously expressed (Zhao et al. 2011) , including in the syncytiotrophoblast microvillous plasma membrane (Carter et al. 2011) , given its dependence on a proton gradient for efficient folate transport it is unlikely to contribute to cellular folate uptake in most cells.
We tested the hypothesis that PCFT is involved in mTOR folate sensing. First, we determined the effect of PCFT silencing on mTORC1 and mTORC2 signalling. To confirm efficient silencing, we performed Western blots on siRNA-transfected cells at 90 h of culture. PCFT siRNA decreased the PCFT protein expression by 80% (P < 0.002; n = 3, data not shown) as compared to control cells. Furthermore, hCG secretion profiles were similar in cells in which PCFT had been silenced as compared to cells incubated in scrambled siRNA (n = 3, data not shown).
As shown in Fig. 7 , PCFT silencing resulted in a marked decrease in phosphorylation of mTOR at Ser-2448 (−36%, P < 0.04; n = 5), S6K at Thr-389 (−71%, P < 0.03; n = 4), S6 ribosomal protein at Ser-235/236 (−73%, P < 0.02; J Physiol 595.13 n = 6-7) and 4E-BP1 at Thr-70 (−49%, P < 0.01; n = 6-7) as compared to cells transfected with scrambled siRNA. No significant differences were found in the expression of raptor between cells transfected with scrambled and PCFT siRNA. Furthermore, PCFT silencing decreased the phosphorylation of SGK at Ser-422 (−69%, P < 0.01; n = 6-7) as compared to control. In contrast, PCFT silencing did not influence the expression of rictor, a protein component of mTORC2. These data demonstrate that PCFT is involved in the regulation of mTORC1 and mTORC2 signalling.
Re-introduction of folate to PCFT-silenced and folate-deficient PHT cells fails to normalize mTOR signalling
To mechanistically link folate, PCFT and mTOR, PHT cells were transfected with PCFT or scrambled siRNA, cultured in control or folate-deficient media until 90 h after plating, followed by culture in folate-containing control media for 10 h. As expected, returning folate-deficient cells transfected with scrambled siRNA to control media completely normalized mTORC1 and mTORC2 signalling activity. Importantly, in cells with PCFT silencing, re-introduction of normal folate concentrations to the cell culture medium at 90 h failed to reverse mTORC1 and mTORC2 activity (n = 3, Fig. 8A , B) These data demonstrate that PCFT is required for mTOR folate sensing.
Requirement of PCFT in mTOR folate sensing is not related to its function mediating cellular folate uptake
One possibility is that the effect of PCFT is indirect due to a decreased cellular folate uptake following PCFT silencing. We have previously shown that mTOR inhibition decreases the expression of specific amino acid transporter ) and folate transporter isoforms (Rosario et al. 2016c) in the plasma membrane. Thus, determining folate uptake following PCFT silencing, which inhibits mTOR (Fig. 7) , may not provide specific information about PCFT-mediated transport. To circumvent this problem we measured folate uptake in PHT cells in which both PCFT and DEPTOR, an endogenous inhibitor of both mTORC1 and 2 signalling that contains two DEP (Dishevelled, Egl-10, Pleckstrin) domains, were silenced (Peterson et al. 2009 ).
We have previously reported that DEPTOR silencing in PHT cells decreases the protein expression of DEPTOR by 55% (Rosario et al. 2016a) . DEPTOR silencing significantly increased the phosphorylation of S6 kinase (Thr-389), 4E-BP1 (Thr-37/46), S6 ribosomal protein (Ser-235/236), functional readouts for mTORC1 and Akt (Ser-473), reflecting the activity of mTORC2 signalling (Rosario et al. 2016a) . Importantly, in cells that were transfected with siRNA for both PCFT and DEPTOR, mTOR activity was maintained at control levels (Fig. 8C) . As shown in Fig. 8D , DEPTOR + PCFT silencing did not affect MTHF uptake in PHT cells at pH 7.4. In contrast, in the presence of a large inwardly directly proton gradient (pH 5.5 in the culture medium), DEPTOR + PCFT silencing markedly inhibited MTHF uptake (Fig. 8E) . These results are consistent with reports that PCFT does not mediate significant MTHF uptake in isolated syncytiotrophoblast microvillous plasma membrane vesicles at physiological pH (Carter et al. 2011) . Thus, the requirement of PCFT in mTOR folate sensing is independent of its role as a plasma membrane folate transporter.
PCFT silencing inhibits folate-mediated mTORC1 activity by disrupting mTOR-LAMP2 lysosomal co-localization
Recent advances in the field of mTORC1 amino acid sensing have placed this cellular process at the surface of the lysosome (Sancak et al. 2008 (Sancak et al. , 2010 . Specifically it is believed that amino acids regulate the recruitment of mTORC1 to the lysosomal surface, where mTORC1 is activated. Conversely, mTORC1 is rapidly removed from the lysosome in amino acid-starved cells, resulting in inactivation of mTORC1 signalling (Efeyan et al. 2012) . We explored co-localization of mTOR and LAMP2, a lysosomal marker, using confocal microscopy and PLA, an approach that allows the in situ detection of interacting endogenous proteins (mTOR/LAMP2). Specifically, we tested the hypothesis that folate promotes co-localization of mTOR and LAMP2, which requires PCFT. In PHT cells transfected with scrambled siRNA, folate deficiency for 90 h resulted in a loss of mTOR/LAMP2 co-localization (yellow, Fig. 9 ). However, changing to folate-containing control media at 90 h restored mTOR/LAMP2 co-localization. Importantly, in cells with PCFT silencing, re-introduction of normal folate concentrations to the cell culture medium at 90 h failed to restore mTORC1 localization at the lysosomal surface. These findings are consistent with the possibility that mTOR folate sensing occurs at the lysosomal surface, which requires PCFT.
Maternal serum folate is associated with placental mTORC1 and mTORC2 signalling in human pregnancy
To explore the clinical relevance of our findings, we examined the relationship between maternal serum folate and placental mTORC1 and mTORC2 signalling in term placenta from a cohort of healthy women (n = 13) undergoing Caesarean section at term. Even in this small cohort, maternal serum folate was positively correlated with birth weight (Fig. 10A) . Consistent with our findings in cultured primary human trophoblast cells we observed a significant positive correlation between maternal serum folate and functional readouts of mTORC1 signalling (Fig. 10B ) and mTORC2 signalling (Fig. 10C, D) .
Discussion
We show for the first time that mTOR functions as a folate sensor, thereby identifying a novel mechanistic link by which folate regulates cell growth and function. Folate sensing by mTOR in PHT cells involves both mTORC1 and C2 and requires the PCFT (SLC46A1). mTOR is trafficked to the lysosome in response to increased folate availability, similar to the mechanisms involved in mTOR amino acid sensing. Our findings are relevant for human physiology because studies were carried out in cultured primary human trophoblast cells. Trophoblast mTOR folate sensing resulting in mTOR inhibition and down-regulation of key placental amino acid transporters could be one mechanism underlying the relationship between low maternal folate levels and restricted fetal growth. Indeed, the clinical relevance of our data is supported by the observation in a small cohort of women that maternal serum folate correlated positively with birth weight and placental mTORC1 and mTORC2 signalling. These findings may have broad biological implications and provide new insights into the mechanisms underpinning the associations between folate availability and diseases such as cancer, fetal growth restriction and fetal malformations.
mTOR nutrient sensing, including regulation of mTOR signalling by amino acids, ATP and oxygen, is a function previously ascribed exclusively to mTORC1. We found that both mTORC1 and mTORC2 are responsive to folate availability, which is, to the best of our knowledge, the first Figure 9 . Folate promotes co-localization of mTOR and LAMP2, which requires PCFT Immunofluorescence confocal microscopy in combination with in situ PLA, which detects protein-protein complexes, was used to explore interactions between mTOR and LAMP2 following PCFT inhibition with folate deficiency/folate re-supplementation. Each detected complex is represented by a yellow dot. DNA was counterstained by DAPI (blue). Scale bar = 20 µm. J Physiol 595.13 report implicating mTORC2 in nutrient sensing. We also show that PCFT is required for mTORC1/2 folate sensing in PHT cells. Intriguingly, although PCFT silencing and folate deficiency, respectively, inhibited mTORC1 and mTORC2 signalling, PCFT silencing regulated 4E-BP1 at a different phosphorylation site (Thr-70) than folate deficiency (Thr-37/46). The mechanism underlying this difference remains to be established. PCFT is ubiquitously expressed, although in most normal cells extracellular pH is slightly higher than cytosolic pH, generating a small outwardly directed proton gradient. Thus, given that PCFT requires a proton gradient to drive folate transport, it is highly unlikely that this transporter mediates folate uptake in normal cells, with some exceptions such as the intestinal epithelium (Desmoulin et al. 2012) . Indeed, we demonstrate in PHT cells that the requirement for PCFT for mTOR folate sensing is not related to its function as a plasma membrane folate transporter. Because the folate transport function of PCFT is dependent on a pH gradient (Qiu et al. 2006) , it has been proposed that PCFT plays an important role in endosomal/lysosomal efflux of folate (Pan et al. 2002; Zhao et al. 2011) . Recent advances in the field of mTORC1 amino acid sensing have placed this cellular process at the surface of the lysosome (Sancak et al. 2008 (Sancak et al. , 2010 . Specifically it is believed that amino acids regulate the recruitment of mTORC1 to the lysosomal surface, where mTORC1 is activated. Interestingly two proton-coupled amino acid transporters, PAT1 and PAT4, located on intracellular membranes, are required for mTORC1 amino acid sensing (Heublein et 2010; Ogmundsdottir et al. 2012) and have been suggested to be an integral part of the multiprotein nutrient sensing complex on the lysosomal surface that mediate mTORC1 amino acid sensing (Jansson et al. 2012 ). Thus, it is possible that PCFT links folate availability to mTORC1 signalling at the lysosome. However, further studies are needed to explore this possibility. Folate deficiency inhibits cell growth and proliferation in HepG2 cells (Huang et al. 1999; Yu et al. 2013) , adult hippocampal progenitor cells (Kruman et al. 2005) and Chinese hamster ovary cells (Borman & Branda, 1989) . Although decreased availability of nucleotide precursors is believed to contribute to impaired cell growth and proliferation in response to folate deficiency, the mechanisms are not known in detail. mTOR is regulated by growth factor signalling and mTORC1 activity is modulated by cellular levels of oxygen, energy, amino acids and glucose (Dennis et al. 2001; Dann et al. 2007; Laplante & Sabatini, 2012; Wiczer & Thomas, 2012) . mTOR signalling is a master regulator of protein translation, thereby controlling cell metabolism, growth and proliferation (Gulati & Thomas, 2007; Thoreen et al. 2012) . In addition, mTOR constitutes a powerful positive regulator of trophoblast amino acid transporters (Roos et al. 2007 (Roos et al. , 2009 Rosario et al. 2013 Rosario et al. , 2016a Chen et al. 2015) . Thus, mTOR-signalling plays a critical role matching cellular nutrient uptake, metabolism and growth with nutrient availability, as reflected by nutrient levels on the cellular level and circulating concentrations of metabolic hormones and growth factors on the organism level. mTOR folate sensing is consistent with this overall integrating role of mTOR signalling because folate is required for the synthesis of purine and thymidine nucleotides constituting DNA building blocks and therefore essential for DNA synthesis. mTOR signalling therefore constitutes a mechanistic link between folate availability and cell growth in proliferative cells. In the human syncytiotrophoblast, mTOR folate sensing may have a critical role in matching placental functions such as nutrient transport, protein translation and mitochondrial function, and therefore fetal growth, to folate availability.
Although the literature is not entirely consistent, several studies demonstrate a strong positive relationship between maternal red blood cell folate and birth weight (Tamura & Picciano, 2006) . Furthermore, a meta-analysis of eight randomized controlled trials investigating the effect of folate supplementation on fetal growth clearly shows a dose-response relationship between folate intake and birth weight (van Uitert & Steegers-Theunissen, 2013) . Albeit a very small cohort, our data are consistent with a positive correlation between maternal folate levels and fetal growth. In addition, the clinical relevance of our findings is supported by the observation in our study that maternal serum folate correlated positively with placental mTORC1 and mTORC2 signalling. Fetal growth is largely determined by nutrient availability and trophoblast mTOR signalling is a positive regulator of placental amino acid transport (Roos et al. 2009; Rosario et al. 2013) . We demonstrate that mTOR signalling in cultured primary human trophoblast cells is highly responsive to changes in folate availability. Furthermore, we show that folate deficiency in PHT cells causes a marked down-regulation of amino acid transport. Importantly, we have previously reported that mTORC1 and mTORC2 specifically regulate the plasma membrane trafficking of SNAT 2 (sodium-dependent neutral amino acid transporter 2) and LAT 1 (large neutral amino acid transporter 1), but no other System A/L isoform, in cultured primary human trophoblast cells . Because trophoblast nutrient transport plays a critical role in determining fetal growth , folate sensing by trophoblast mTOR may represent a mechanism by which maternal folate status modulates fetal growth and development. We therefore propose that inhibition of trophoblast mTOR signalling, resulting in down-regulation of key placental amino acid transporters and decreased fetal nutrient availability, constitutes one mechanism underlying the association between low maternal folate levels and restricted fetal growth.
Our findings may have relevance beyond trophoblast function and fetal growth given the critical role of folate in normal cell function and the wide range of disorders that are caused by folate deficiency. Periconceptional folate deficiency is a risk factor for fetal structural malformations such as NTDs (Czeizel & Dudas, 1992; Blom et al. 2006) . Although changes in DNA methylation and alterations in synthesis of nucleotide precursors have been implicated (Smithells et al. 1976; Wilde et al. 2014) , the mechanism by which folate affects neutral tube closure remains poorly understood. Folate deficiency or impaired folate metabolism is also associated with an increased risk of developing cancer (Duthie, 2011) , which is believed to be due to impaired DNA repair. Intriguingly, emerging evidence suggests that also high folate intake promotes carcinogenesis (Glynn & Albanes, 1994; Ulrich, 2007; Wien et al. 2012) , although the underlying molecular mechanism remains elusive. mTOR activation is a common finding in cancer and it may be speculated that mTOR folate sensing, causing activation of mTOR signalling in response to increased folate availability, could be one mechanism underlying the link between high folate and increased cancer risk.
In conclusion, we have identified a novel specific molecular link between folate availability and fetal growth, which involves trophoblast PCFT and mTOR. We propose that mTOR folate sensing in trophoblast cells matches placental nutrient transport and fetal growth to maternal folate status.
